PFE
Pfizer Inc.
Stock$24.89
+$0.22 (+0.89%)
Current Price (API): $24.89About
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Price History (Last 30 Days)
Latest News & Updates
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.
Pfizer's 6.8% dividend yield significantly exceeds market averages, raising conc...
Pfizer's 6.8% dividend yield significantly exceeds market averages, raising concerns about sustainability. However, management remains committed to maintaining and growing the dividend, as evidenced by Q1 2026 earnings presentations. The company generated sufficient operating cash flow to cover dividend payments and maintain a higher cash balance, supported by $11.3 billion in long-term investments. While Pfizer faces industry headwinds including patent expirations and delays in GLP-1 drug development, analysts suggest the company has the financial capacity to sustain its dividend through this challenging period.
The article recommends three dividend stocks suitable for long-term buy-and-hold...
The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.
A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-...
A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.
Pfizer is positioning itself as a contender in the rapidly growing $100 billion...
Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.
Pfizer's stock has fallen over 50% from late 2021 highs, pushing its dividend yi...
Pfizer's stock has fallen over 50% from late 2021 highs, pushing its dividend yield to a historically high 6.9%. While the company faces normal industry headwinds including upcoming patent expirations and disappointing new drug development, management remains committed to protecting the dividend. The company is taking steps to address challenges, including acquiring a weight-loss drug candidate after dropping its own GLP-1 drug. More aggressive dividend investors may find Pfizer's valuation compelling despite risks.
Pfizer's attractive 7% dividend yield masks significant risks as the company fac...
Pfizer's attractive 7% dividend yield masks significant risks as the company faces a patent cliff with major drugs losing protection in 2027-2028. With a dividend payout ratio over 130% and limited new drug candidates in the pipeline, investors are concerned about the sustainability of the dividend. However, the company has cash reserves and debt options to maintain payments, and management has prioritized dividend preservation.
The New Civil Liberties Alliance filed an amicus curiae brief with the U.S. Supr...
The New Civil Liberties Alliance filed an amicus curiae brief with the U.S. Supreme Court in the Boysen v. PeaceHealth case, arguing that courts have misinterpreted the 1905 Jacobson v. Massachusetts decision to justify broad vaccine mandates. NCLA contends that Jacobson should only permit mandates when vaccines prevent disease transmission to third parties, and that lower courts have failed to protect individuals' liberty interests in refusing unwanted medical treatment.
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinfor...
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.
The global autoimmune disease therapeutics market is projected to grow from USD...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.
